Abstract-Gas-filled microbubbles have the potential to become a unique intravascular MR contrast agent due to their magnetic susceptibility effect, biocompatibility and localized manipulation via ultrasound cavitation. However, in vivo demonstration of microbubble susceptibility effect is limited so far and microbubble susceptibility effect is relatively weak when compared with other intravascular MR susceptibility contrast agents. In this study, two types of microbubbles, custom-made albumin-coated microbubbles (AMBs) and a commercially available lipid-based clinical ultrasound contrast agent (SonoVue®), were investigated with in vivo dynamic brain and liver MRI in Sprague-Dawley rats at 7 Tesla. Transverse relaxation rate enhancements (ΔR 2 * ) maps were computed for brain and liver, yielding results similar to those obtained with a common MR blood pool contrast agent. These results indicate that gas-filled microbubbles can serve as an intravascular MR contrast agent at high field. Enhancement of microbubble susceptibility effect by entrapping monocrystalline iron oxide nanoparticles (MIONs) into microbubbles was also investigated at 7 T in vitro. This is the first experimental demonstration of microbubble susceptibility enhancement for MRI application. This study indicates that gas-filled microbubble susceptibility effect can be substantially increased using iron oxides nanoparticles. With such approach, microbubbles can potentially be visualized with higher sensitivity and lower concentrations by MRI. Such capability has the potential to lead to real-time MRI guidance in various microbubble-based drug delivery and therapeutic applications.
I. INTRODUCTION as-filled microbubles can potentially be used as an intravascular MR susceptibility contrast agent in vivo due to the induction of large local magnetic susceptibility difference by the gas-liquid interface. Moreover, microbubbles can be locally cavitated and destroyed by focused ultrasound [1] , hence the MR signals can be temporally and spatially manipulated because microbubble disappearances will diminish the susceptibility effect. Recently, microbubbles have been employed in therapeutic applications due to their unique cavitation [2] and sonoporation [3] properties. Site-specific release of incorporated drugs or genes inside microbubbles can be achieved with local microbubble cavitation by spatially focused ultrasound. Microbubble-mediated sonoporation can dramatically increase cell permeability and intracellular uptake [4] , with substantial increase in gene transfection efficiency and therapeutic effectiveness being demonstrated. Furthermore, several therapeutic interventions, like sonothrombolysis [5] , transient opening of blood-brain barrier potentially for delivery of both low and high molecular weight therapeutic compounds [6] and enhancing the high intensity focused ultrasound therapy by increasing the local heating rate [7] have been demonstrated. Early experiment with Albunex®, an ultrasound contrast agent consisting of air-filled microbubbles with human albumin shell, illustrated the potential of air-filled microbubbles as an MR susceptibility contrast agent [8] . Feasibility of microbubbles as an MR pressure sensor, based on the susceptibility change caused by pressure-induced microbubble size change, has been explored through theoretical [9] and phantom [10] studies. The first in vivo investigation of susceptibility contrast induced by microbubbles was reported by our group previously using Optison®, microbubbles of human albumin shells with perfluorocarbon as core gas, at 7 T in rat liver [11] . R 2 * dependency on microbubble volume fraction was also reported for Levovist®, air-filled microbubbles with palmitic acid shells, through an in vitro phantom study at 1.5 T [12] . Magnetic susceptibility enhancement induced by gas-liquid interface was demonstrated recently by simulations and MR experiments using air-filled cylinders in water [13] , consolidating the feasibility of gas-filled microbubbles as an MR susceptibility contrast agent. However, in vivo demonstration is limited so far and microbubble susceptibility effect is still relatively weak when compared with other intravascular MR susceptibility contrast agents [11, 14] . In this study, we aim to further investigate and demonstrate the in vivo MR susceptibility effect induced by both custom-made albumin-coated microbubbles and commercially available lipid-based microbubbles in rat brain and liver at 7 T using dynamic susceptibility weighted MRI, and experimentally demonstrate that microbubble R 2 * can be enhanced by embedded or entrapping monocrystalline iron oxide nanoparticles (MIONs) [15] into microbubble shells.
II. METHODOLOGY
All MRI experiments were performed on a 7 T MRI scanner with a maximum gradient of 360 mT/m (70/16 PharmaScan, Bruker Biospin GmbH, Germany). All animal experiments were approved by the local institutional animal ethics committee.
A. Microbubble Preparation A commercially available clinical ultrasound contrast agent (SonoVue®, Bracco, Milan, Italy), was used in this study. SonoVue® microbubbles consist of sulphur hexafluoride gas stabilized in an aqueous dispersion by a phospholipid monolayer. Air-filled custom-made albumin-coated microbubbles (AMBs) were produced by sonication as previously described [16] . AMBs with MIONs embedded in shells were synthesized [17] . Polymeric microbubbles (PMBs) with MIONs incorporated or entrapped in shells were produced by adapting a double emulsion procedure [17] . MION-free PMBs were synthesized with the same procedure except using deionized water instead of the MION solution.
B. Animal Preparation and Microbubble Administration Ten normal adult Sprague-Dawley rats (~250-350 g) were used. Each rat was anesthetized with intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Femoral vein catheterization was performed. During imaging, animals were anesthetized with isoflurane/air using 1.0-1.5% via a nose cone with respiratory monitoring. Microbubbles were first warmed slowly to room temperature. Resuspension was performed until a homogenous milky-white suspension formed. For each imaging session, 0.2 mL of microbubble suspension (of ~4% volume fraction for AMBs and ~3.5% volume fraction for SonoVue®) was slowly injected (over ~10 s) into femoral vein at a rate of 1.2 mL/min to avoid possible microbubble destruction due to high pressure and shear stress.
C. Susceptibility Contrast Imaging of Rat Brain In vivo brain imaging was performed in rats (N = 5) using a 38-mm quadrature resonator. Anatomical images were acquired with two-dimensional (2D) fast low-angle shot (FLASH) sequence. Dynamic susceptibility weighted MRI was performed with single-shot GE echo-planner imaging (GE-EPI) sequence using TR = 1000 ms, TE = 30 ms, flip angle = 90º, acquisition matrix = 96 × 96, spatial resolution = 0.3 × 0.3 × 0.7 mm 3 and NEX = 1. Microbubble suspension was injected about 5 min after the start of dynamic imaging. A minimum lapse of 10 min was used to ensure sufficient clearance of the microbubbles before the next injection. The susceptibility effect of microbubbles was compared with that of MIONs [18] [19] [20] in brain by a single dose of 0.6 mg Fe/kg injection using identical injection protocol and imaging sequence.
D. Susceptibility Contrast Imaging of Rat Liver
Liver imaging was performed in rats (N = 5) using a 60-mm quadrature resonator. Dynamic MRI was then performed with respiratory-gated of similar protocol as brain imaging, except that TE = 10 ms, acquisition matrix = 64 × 64, spatial resolution = 0.78 × 0.78 × 2.0 mm 3 and NEX = 1. The susceptibility effect of microbubbles was also compared with that of MIONs in liver by a single dose of 0.6 mg Fe/kg injection.
E. In vivo Data Analysis GE-EPI images were first co-registered using AIR5.2.5 [21] . Apparent transverse relaxation rate enhancement (ΔR 2 * ) maps were computed on a pixel-by-pixel basis as ΔR 2 * = ln (S pre /S avg-post )/TE [22] . Assuming that ΔR 2 * is proportional to microbubble concentration C(t) at time t, C(t) can be estimated as C(t) = k ln {S pre /S(t)}/TE + C B , where S(t) is the image intensity at time t, k a proportionality constant, and C B a constant residue to account for any postinjection baseline [11] . Given the relatively long injection time and the limited lifetime of microbubbles in vivo, C(t) were approximately modeled with a gamma-variate function by curve fitting [23] . Full width at half maximum (FWHM) and time-to-peak were then measured from the fitted C(t) time courses.
F. Ultrasound Demonstration Ultrasound imaging (Sonix RP, Ultrasonix) was preformed in rat livers (N = 2) using SonoVue® to demonstrate microbubble induced contrast change for comparison.
G. Measurement of ΔR2* of MION-free and MION-entrapped AMB and PMB Suspensions Microbubble phantom study was performed with 38-mm quadrature resonator. AMBs were diluted from a well-mixed microbubble suspension to 4% volume fraction with the addition of saline, while PMBs of 5 % volume farction were prepared by addition of saline. The microbubbles were then placed in separate 2-mL cylindrical phantom tubes. Each phantom tube was slowly warmed to room temperature and gently mixed for 2 min outside the magnet prior to MR measurements. To ensure uniform suspension of microbubbles, the phantom was then continuously stirred by rotation inside the magnet. It was then arrested in horizontal position immediately before the start of MR acquisition sequence. ΔR 2 * was measured by acquiring multi-echo GE signals continuously without phase encoding for 2 min from an axial 1-mm slice at middle of the phantom as previously described [17] . Microbubble induced ∆R 2 * was then calculated as the difference between R 2 * in the initial state and that in the final state. To demonstrate that MION were embedded and entrapped, microbubble-free suspending solutions R 2 * was measured before and after cavitation (using ultrasound of frequency 40 kHz) with multiple gradient echo sequences.
III. RESULTS AND DISCUSSIONS

A. Characterization of AMBs and SonoVue®
The light micrographs of a representative batch of AMBs and SonoVue® microbubbles were depicted in Figs. 1(a) and (b) , respectively. The estimated size distribution was from 1 to 23 µm (with 9.21 µm mean diameter) for AMBs and 1 to 10 µm (with 2.95 µm mean diameter) for SonoVue®. Fig. 2 shows the dependency of ∆R 2 * on microbubble volume fractions in AMBs and SonoVue® microbubble suspension phantoms. An approximately linear relationship was observed. The relaxivities estimated from the fitted slopes were 58.52 (s · volume fraction) -1 and 52.94 (s · volume fraction) -1 for AMBs and SonoVue®, respectively, consistent with the microbubble susceptibility effect in a theoretical study [9] . Fig. 3 illustrates the rat brain images typically observed during AMBs injection. Note that the microbubbles induced ∆R 2 * maps were observed to be similar to those caused by intravascular MION. Similar results were observed for SonoVue® injection. Table 1 shows the in vivo measurements of ∆R 2 * , FWHM and time-to-peak of AMBs and SonoVue®, as well as ∆R 2 * and time-to-peak of MION in cortex area among all rats studied. Time-to-peak of microbubbles was found to be longer than that of MION. This is largely expected as microbubbles, with size comparable to that of red blood cells, flow slower than blood plasma while MION nanoparticles flow together with plasma. In few of the rats studied (1 out of 5 in brain imaging), the T 2 * -weighted signals after microbubble injection did not return to the preinjection baseline, this may be caused by microbubble trapping in local tissue vasculature. Fig. 4 illustrates the rat liver images typically observed during AMBs and SonoVue® injection. The signal time course during SonoVue® injection captured by ultrasound imaging was overlaid in grey for comparison. Note that the ultrasound signal was enhanced by microbubbles. Similar signal recovering patterns were observed, showing comparable lifetime of SonoVue® in vivo. Table 1 shows the measured ∆R 2 * , FWHM and time-to-peak of AMBs and SonoVue®, as well as ∆R 2 * and time-to-peak of MION in liver. Time-to-peak of microbubbles was also found to be longer than that of MION. In few of the rats studied (2 out of 5 in liver imaging), the T 2 * -weighted signals after microbubble injection did not return to the preinjection baseline, possible uptake of intact microbubbles by Kupffer cells in liver may also contribute to such observation. Table 1 . In vivo measurements of relaxation rate enhancement (∆R 2 * ), full width at half maximum (FWHM) and time-to-peak of the concentration time courses for AMBs, SonoVue® and MIONs in rat brain cortex (mean ± standard deviation, N = 5) and liver (mean ± standard deviation, N = 5). without and with MIONs after cavitation were found to be increased by 0.3 ± 0.4 s -1 and 55 ± 9 s -1 respectively. These substantial differences for microbubbles with MIONs demonstrate that there were more MIONs in the suspending solution after cavitation; suggesting that embedded and entrapped MION were released into suspending solution after the microbubble cavitation. Transmission electron microscopy was done on AMBs with MION and depicted in Fig. 6 . MIONs as dark dots (red arrows) were observed on the shells of AMB, validating MIONs were embedded onto shells of AMBs. Nevertheless, small amount of free MIONs were also observed in suspending solution (green arrow). Larger iron oxide nanoparticles like superparamagnetic iron oxide nanoparticles (SPIOs) or FePt@Fe 2 O 3 yolk−shell nanoparticles [24] , may be used to further enhance the microbubble magnetic susceptibility effect [25] .
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IV. CONCLUSIONS In this study, we investigated the feasibility of gas-filled microbubbles as an intravascular MR susceptibility contrast agent in vivo at 7 T. Considerable susceptibility induced changes were observed and characterized in rat brain and liver using the custom-made albumin-coated microbubbles and a commercially available clinical ultrasound microbubble contrast agent. The results indicate that microbubbles can serve as a unique intravascular MR contrast agent at high field. We also demonstrated, for the first time, that embedding or entrapping iron oxide nanoparticles in microbubbles is feasible. With such approach, microbubble susceptibility can be significantly enhanced, so that microbubbles can be monitored with high sensitivity and low concentrations under MRI. Such capability has the potential to lead to real-time MRI guidance in various microbubble-based drug delivery and therapeutic applications. 
